Chronic Pain Market: Insights, Epidemiology Facts, Forecast Report 2032

DelveInsight’s Chronic Pain Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Chronic Pain market share of the individual therapies, current and forecasted Chronic Pain market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Chronic Pain Overview

Pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. It may be due to an injury or to the brain’s inability to process pain signals properly. Pain is classified as either acute or chronic. Acute pain is usually severe and short-lived (normally 3 months), and is often the result of a disease that may require ongoing treatment.

 

Chronic Pain Epidemiology Insights

The Chronic Pain epidemiology division provides insights about historical and current Chronic Pain patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken

 

Some of the key highlights of the Chronic Pain market report

Out of 24,925 respondents (52.2% female, mean age 51.5 years), 15,751 (63.7%) respondents were found to be having pain. Out of this, 2,548 (15.7%) had probable NeP based on the PainDetect, which was 10% of all respondents.
Overall, the prevalence of chronic pain was 20.4%, and the prevalence of high-impact chronic pain was 7.4%, but women were more likely to have chronic pain (21.7%) and high-impact chronic pain (8.5%) compared with men (19.0% and 6.3%, respectively).
Chronic Pain market companies are included like Pfizer/Eli Lilly and Company, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, Allergan [acquired by ABBVie], Stayble Therapeutics, Aptinyx, Lateral Pharma, Eli Lilly and Company, Samumed, and many others.
Chronic Pain therapies are included like Vyepti (Eptinezumab-jjmr), Tarlige (Mirogabalin), Fasinumab, Lorecivivint, and many others.

 

Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/chronic-pain-market

 

Chronic Pain symptoms include-

Pain may occur with other symptoms depending on the underlying disease, disorder, or condition. For instance, if the pain is due to arthritis, the patient may experience pain in more than one joint. Chronic pain often leads to signs (e.g lassitude, sleep disturbance, decreased appetite, loss of taste for food, weight loss, diminished libido, constipation), which develop gradually. Constant, unremitting pain may lead to depression and anxiety and interfere with almost all activities. Patients may become inactive, withdraw socially, and become preoccupied with physical health. Psychologic and social impairment may be severe, causing a virtual lack of function.

Chronic Pain Diagnosis include-

Diagnosing chronic pain is not easy, as there are no tools to quantify pain. Diagnosis often involves a series of tests and procedures, as well as a review of symptoms and medical history. There is no way to measure pain objectively. Only the person with chronic pain can describe how much pain he or she is feeling.

 

Chronic Pain Treatment includes-

There are several categories of medications that are used for the treatment of chronic pain. Oral medications include those that can be taken by mouth, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, opioid-like agents, or combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants.

 

Chronic Pain Sources

The most common sources of chronic pain include low back pain, headache (migraine), neuropathic pain (Neuralgia), musculoskeletal pain (Fibromyalgia), cancer pain, post-operative pain, arthritic pain (Osteoarthritis, Rheumatoid Arthritis), and others. Chronic pain can cause significant psychological and emotional trauma and often limits an individual’s ability to function fully. It is a common complaint in older adults. A person may have more than one chronic pain condition at a time. Someone may experience chronic pain long after they are injured or without any apparent cause. In some cases, more than one factor may be involved.

 

 Chronic Pain Market Report Scope

The report covers the descriptive overview of Chronic Pain, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
Comprehensive insight has been provided into the Chronic Pain epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Chronic Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Pain market.

 

Chronic Pain Market Companies

Pfizer/Eli Lilly and Company
Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation
Allergan [acquired by ABBVie]
Stayble Therapeutics
Aptinyx
Lateral Pharma
Eli Lilly and Company
Samumed
Sorrento Therapeutics, and others.

 

Learn More about Key Players working in the domain @ https://www.delveinsight.com/sample-request/chronic-pain-market

 

Chronic Pain Therapies

Vyepti (Eptinezumab-jjmr)
Tarlige (Mirogabalin)
Ajovy (Fremanezumab)
Fasinumab
Lorecivivint (SM04690), and others

 

Get detailed information about the pipeline therapies @ https://www.delveinsight.com/sample-request/chronic-pain-market

 

Chronic Pain Emerging Drugs

Tanezumab (Pfizer/Eli Lilly and Company)
Fasinumab/REGN475 (Regeneron Pharmaceuticals/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation)
Atogepant (Allergan [acquired by ABBVie])
Ampion (Ampio Pharmaceuticals)
Rexlemestrocel/MPC-06-ID (Gruenthal/Mesoblast)

 

Table of content

Key Insights
Report Introduction
Market Overview at a Glance
Executive Summary
Epidemiology and Market Methodology
Disease Background and Overview
Diagnosis of Chronic Pain
Current Treatment
Epidemiology and Patient Population
The United States
EU-5
Japan
Patient Journey
Key Endpoints in Chronic Pain Clinical Trials
Marketed Therapies
Emerging Therapies
7 Major Market Analysis
The United States Market Size
EU-5 Market Size
Japan
Market Access and Reimbursement
Market Drivers
Market Barriers
SWOT Analysis
Unmet Needs
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

 

Connect with our Business Consultant @ https://www.delveinsight.com/sample-request/chronic-pain-market

 

About Us

DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/